Because of negative connotations and stigma associated with the term "monkeypox," WHO will fade out the term and use "mpox" in its place.
(Adobe Stock)
This article first appeared on Contagionlive.com.
World Health Organization (WHO) announced it has recommended changing the name of monkeypox to mpox. Both names will be used simultaneously for one year while “monkeypox” is phased out.
The organization announced several months ago they were looking to rename the virus as it had some negative connotations and stigma associated with it. The WHO will adopt the term mpox in its communications and encourages others to follow these recommendations to minimize any ongoing negative impact of the current name and from adoption of the new name.
According to a WHO statement, the organization recommends the following:
Assigning names to new and, very exceptionally, to existing diseases is the responsibility of WHO under the ICD and the WHO Family of International Health Related Classifications through a consultative process, which includes WHO Member States.
WHO, in accordance with the ICD update process, held consultations to gather views from a range of experts, as well as countries and the general public, who were invited to submit suggestions for new names.
Back in the summer, both the Biden Administration and the WHO declared monkeypox as public health emergencies as the incidence rates increased dramatically in different hot spots across the globe.
Although caseloads have been decreasing in the last several weeks, a public health concern remains as it is seemingly mysterious why the outbreak started earlier this year in the first place.
Treatment
CDC and the Food and Drug Administration (FDA) developed a process to help clinicians secure an antiviral therapy, tecovirimat (Tpoxx), for monkeypox treatment. This falls under the expanded access investigational new drug (EA-IND). Clinicians can secure tecovirimat by going here.
Tecovirimat is manufactured by SIGA Technologies, and is approved for smallpox and is being studied for monkeypox treatment. Infection Control Today®’s sister brand, ContagionLive®, spoke with SIGA Technologies Chief Scientific Officer Dennis Hruby, PhD, earlier this year about the therapy.
Together We Rise: Why AORN Expo 2025 Is a Must for Every Perioperative Nurse
March 31st 2025From April 5 to 8, 2025, thousands of perioperative nurses will gather in Boston for the 2025 AORN Global Surgical Conference & Expo—a transformational experience designed to elevate nursing practice, build lifelong connections, and advance surgical care.
Vet IP Roundtable 2: Infection Control and Biosecurity Challenges in Veterinary Care
March 31st 2025Veterinary IPs highlight critical gaps in cleaning protocols, training, and biosecurity, stressing the urgent need for standardized, animal-specific infection prevention practices across diverse care settings.
Invisible, Indispensable: The Vital Role of AHRQ in Infection Prevention
March 25th 2025With health care systems under strain and infection preventionists being laid off nationwide, a little-known federal agency stands as a last line of defense against preventable patient harm. Yet the Agency for Healthcare Research and Quality (AHRQ) is now facing devastating cuts—threatening decades of progress in patient safety.